Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s):  AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.


CSE:AGN - Post by User

Post by wiseinvestor2on Feb 10, 2016 11:47am
205 Views
Post# 24543872

Breathtec Biomedical Inc. C.BTH

Breathtec Biomedical Inc. C.BTH

Hello, and welcome to Breathtec Biomedical. Our company was formed to advance research and development of some truly innovative techniques in the area of early stage medical diagnostic screening aids through breath analysis. Researchers have been investigating blood-breath analysis for a number of years now, but its only recently that advances in detection equipment has reached the point where the possibility of miniaturized and highly specialized medical devices could be constructed for use in front line environments such as a general practitioners medical office. Until now, the technology was unwieldy, required special training, and was excessively expensive to own and operate.We at Breathtec believe this is all about to change.

Our goal is to deliver a device that can be commercialized as a highly effective rapid screening tool for identifying early stage disease bio-markers as well as offering quick and painless means to monitor certain diseases to ensure treatment efficacy on an ongoing basis. We envision a future where a trip to the doctors office could determine early signs of breast and lung cancers, alzheimer’s and parkinson’s, tuberculosis, diabetes, liver disease and more, all with just a single breath sample. And its worth noting that results can be made available in moments instead of days.

An ambitious vision perhaps, but one that we feel is achievable and certainly worth pursuing. While it may be difficult to put a dollar figure on the savings achieved through early treatment and resulting quality of life and productivity which might otherwise might be lost, I think it safe to say the value of early screening could be measured in billions of dollars annually around the globe. To that end, we have already secured a key patent in this potentially high growth sector, and are working diligently to ensure we achieve a leading role in future developments.

Our vision today is what drives us. A future where safer, less intrusive, painless, low cost and faster means to better health can be turned into reality.

I invite you to read our website, and feel free to contact usfor more information. Please sign up to receive our news alerts as we hope you will follow our progress towards a healthy future.

Sincerely,

Michael T. Costanzo, Ph.D., Chief Executive Officer

Breathtec Biomedical, Inc.

Bullboard Posts